In CT26 colon cancer cells and B16-F10 melanoma cells, targeting PIK3C3 with siRNA or PIK3C3 inhibitors reduced autophagy and tumor growth and improved mouse survival by inducing the infiltration of natural killer, CD8+, and CD4+ T effector cells [105] (Figure 3). Here, CD8A is linked to melanoma.